Company intelligence / Profile preview
āshibio
Brisbane, California, United Statesashibio.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
āshibio has exited stealth mode with $40M in seed and Series A funding. Its lead asset, andecaliximab, will enter a Phase 2/3 trial for FOP. The company aims to address severe unmet needs in rare bone/connective tissue diseases using innovative therapeutic approaches. No clinical results have been published yet as trials are about to begin
- Therapeutic areas
- RheumatologyRare Diseases
- Modalities
- biologics/monoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
MPM BioImpact (lead investor)Agent CapitalYK BioventuresMirae Asset Venture Investment
Beyond the preview
Go deeper on āshibio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on āshibio.